Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

<p><b>A,</b> Mean NMR spectra for samples from unwell patients with either confirmed solid tumor diagnoses (red, <i>n</i> = 17) or confirmed noncancer diagnoses (black, <i>n</i> = 175). <b>B,</b> Difference spectrum showing regions that were incr...

Полное описание

Сохранить в:

Библиографические подробности
Главный автор:	James R. Larkin (14936324) (author)
Другие авторы:	Susan Anthony (15039111) (author), Vanessa A. Johanssen (15039114) (author), Tianrong Yeo (15039117) (author), Megan Sealey (12045959) (author), Abi G. Yates (14029965) (author), Claire Friedemann Smith (15039120) (author), Timothy D.W. Claridge (15039123) (author), Brian D. Nicholson (2889917) (author), Julie-Ann Moreland (15039126) (author), Fergus Gleeson (4055239) (author), Nicola R. Sibson (14936336) (author), Daniel C. Anthony (15039129) (author), Fay Probert (849357) (author)
Опубликовано:	2025
Предметы:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Methods and Technology Biomarkers Diagnostic biomarkers Early detection biomarkers Liquid Biopsy Metabolism Metabolomics Tumor Staging
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Supplementary Table S4 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
по: Chaoyang Zhang (15051876)
Опубликовано: (2025)

Supplementary Table S6 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
по: Chaoyang Zhang (15051876)
Опубликовано: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
по: Iris van 't Erve (15054503)
Опубликовано: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
по: Kala Visvanathan (14952973)
Опубликовано: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
по: Emil Christensen (15054394)
Опубликовано: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
по: Emil Christensen (15054394)
Опубликовано: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
по: Ismael Fernández-Miranda (15051932)
Опубликовано: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
по: Sofie H. Tolmeijer (15313251)
Опубликовано: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
по: Sofie H. Tolmeijer (15313251)
Опубликовано: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
по: Sofie H. Tolmeijer (15313251)
Опубликовано: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
по: Lavanya Sivapalan (15314248)
Опубликовано: (2025)

Integrating urinary metabolomics and clinical datasets for multi-cancer detection
по: Dongyong Lee (18786694)
Опубликовано: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
по: Andrew A. Davis (15030032)
Опубликовано: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
по: Morten Lapin (15056728)
Опубликовано: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
по: Morten Lapin (15056728)
Опубликовано: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
по: Morten Lapin (15056728)
Опубликовано: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
по: Nam Q. Bui (14958210)
Опубликовано: (2025)

Data Sheet 3_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
по: Hailong Pang (12841991)
Опубликовано: (2025)

Data Sheet 2_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
по: Hailong Pang (12841991)
Опубликовано: (2025)

Data Sheet 1_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
по: Hailong Pang (12841991)
Опубликовано: (2025)

ROC curve analysis of a set of biomarkers obtained via untargeted metabolomics in serum samples from children infected with DENV compared to Control.
по: Ricardo E. Correa Fierro (22676430)
Опубликовано: (2025)

Workflow of untargeted metabolomics in serum samples from children infected with DENV.
по: Ricardo E. Correa Fierro (22676430)
Опубликовано: (2025)

Table 1_Cross-species validation of a 6-miRNA blood signature for Parkinson’s disease: from MPTP mice to human PBMC and serum exosomes.docx
по: Nagyum Jung (22686458)
Опубликовано: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
по: Jun Wang (15051911)
Опубликовано: (2025)

PLS-DA regression model from untargeted metabolomics of serum samples from children infected with dengue and controls.
по: Ricardo E. Correa Fierro (22676430)
Опубликовано: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
по: Katleen Janssens (15053356)
Опубликовано: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
по: Ankita Mitra (17141783)
Опубликовано: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
по: Jamunarani Veeraraghavan (16461809)
Опубликовано: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
по: Jamunarani Veeraraghavan (16461809)
Опубликовано: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
по: Jamunarani Veeraraghavan (16461809)
Опубликовано: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
по: Jamunarani Veeraraghavan (16461809)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_74letsncsnlrf8olvlm1h6u3bg